Financial PerformanceCureVac reported receiving a €400M upfront payment from GSK for COVID-19/flu, significantly boosting its estimated pro forma cash to €602.5M.
Oncology AdvancementsCureVac continues to advance its oncology efforts by planning to select two off-the-shelf clinical candidates for shared-antigen vaccines in solid tumors and hematological cancers by the end of 2025.
Strategic FocusCureVac plans to focus on therapeutic opportunities in oncology and infectious diseases, reflecting a strategic shift towards high-impact areas.